General Hospital Of Athens Korgialenio Benakio H.R.C.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The 1st Cardiology Clinic at General Hospital Of Athens Korgialenio Benakio H.R.C. focuses on preventing clot‑related events such as ischemic stroke. It also evaluates new anticoagulant strategies for patients with atrial fibrillation.
- Oral FXIa inhibitor asundexian for secondary stroke prevention
- Comparison of asundexian with apixaban in atrial fibrillation
- Assessment of major bleeding risk with novel anticoagulants
These studies aim to improve outcomes for high‑risk cardiovascular patients while carefully monitoring safety.
Bacterial Infections and Mycoses
The clinic conducts research on severe infections, employing biomarker‑guided approaches to reduce use of broad-spectrum antibiotics. One focus is the integration of procalcitonin testing to tailor therapy duration.
- Procalcitonin‑guided antibiotic stewardship
- Molecular diagnostics for rapid pathogen identification
- Reduction of treatment duration in severe infections
The objective is to optimize antimicrobial use, limit resistance, and ensure effective patient care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 38 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Of Athens Korgialenio Benakio H.R.C.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 38 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Asundexian | 2 | Unknown | 2022-11-24 | 2023-01-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.